1. Home
  2. PYXS

as of 02-09-2026 3:44pm EST

$1.37
$0.13
-8.67%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Founded: 2018 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 71.6M IPO Year: 2021
Target Price: $6.75 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.57 EPS Growth: N/A
52 Week Low/High: $0.83 - $5.55 Next Earning Date: 03-17-2026
Revenue: $2,820,000 Revenue Growth: -82.53%
Revenue Growth (this year): -82.24% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: -72374000.0 FCF Growth: N/A

AI-Powered PYXS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 73.13%
73.13%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Pyxis Oncology Inc. News

PYXS Breaking Stock News: Dive into PYXS Ticker-Specific Updates for Smart Investing

All PYXS News

Share on Social Networks: